Virtu Financial LLC Invests $316,000 in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Virtu Financial LLC bought a new position in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 20,576 shares of the company's stock, valued at approximately $316,000. Virtu Financial LLC owned about 0.07% of ClearPoint Neuro as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. AlphaQuest LLC purchased a new position in ClearPoint Neuro in the fourth quarter worth about $80,000. Bradley Foster & Sargent Inc. CT purchased a new position in shares of ClearPoint Neuro in the 4th quarter worth approximately $871,000. R Squared Ltd bought a new position in shares of ClearPoint Neuro during the 4th quarter valued at approximately $32,000. Parsons Capital Management Inc. RI raised its holdings in ClearPoint Neuro by 1.9% during the 4th quarter. Parsons Capital Management Inc. RI now owns 141,573 shares of the company's stock valued at $2,177,000 after buying an additional 2,600 shares during the period. Finally, Conway Capital Management Inc. lifted its position in ClearPoint Neuro by 13.9% in the fourth quarter. Conway Capital Management Inc. now owns 161,225 shares of the company's stock worth $2,480,000 after buying an additional 19,725 shares during the last quarter. 30.08% of the stock is currently owned by hedge funds and other institutional investors.

ClearPoint Neuro Stock Performance

CLPT stock traded up $1.20 during midday trading on Tuesday, reaching $13.09. The company's stock had a trading volume of 314,094 shares, compared to its average volume of 213,592. ClearPoint Neuro, Inc. has a 1 year low of $5.11 and a 1 year high of $19.22. The firm has a market capitalization of $361.70 million, a price-to-earnings ratio of -18.97 and a beta of 1.06. The stock has a fifty day simple moving average of $15.56 and a two-hundred day simple moving average of $14.05.

Remove Ads

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. The company had revenue of $7.77 million during the quarter, compared to analysts' expectations of $8.23 million. As a group, analysts forecast that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on CLPT shares. Stifel Nicolaus boosted their price objective on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday. B. Riley increased their price objective on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Finally, Lake Street Capital raised their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a "buy" rating in a research note on Tuesday, January 21st.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.